MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Positive DA-1726 16-Week Phase 1 Part 3 Interim Data Support Planned Phase 2 Development in MetALD and ALDAppointed Sarah Browne, M.D., as Chief Medical Officer to Help Lead the Next Stage of Clinical Development for DA-1726 and VanoglipelFull Data From the Phase 1 Parts 3A and 3B Expected in the F…